A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells

British Journal of Pharmacology

Volumn 171, Issue 21, 2014, Pages 4820-4830

  Park, Ki Cheong ^a   Park, Ji Hyun ^a   Jeon, Jeong Yong ^a   Kim, Sang Yong ^a   Kim, Jung Min ^a   Lim, Chang Yong ^b   Lee, Tae Hyung ^a   Kim, Hyung Kwan ^a   Lee, Hyun Gyu ^a   Kim, Sung Min ^a   Kwon, Ho Jeong ^c   Suh, Jin Suck ^a   Kim, Seung Won ^a   Choi, Seung Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFIBROTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOOXYGENASE 2; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELOXICAM; N HYDROXY 7 (2 NAPHTHYLTHIO)HEPTANOMIDE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTIN; COLLAGEN TYPE 1; GELATINASE A; GELATINASE B; HYDROXAMIC ACID; MMP2 PROTEIN, RAT; MMP9 PROTEIN, RAT; N-HYDROXY-7-(2-NAPHTHYLTHIO)HEPTANAMIDE; NAPHTHALENE DERIVATIVE; PTGS2 PROTEIN, RAT; SMOOTH MUSCLE ACTIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT LIGATION; BILIRUBIN BLOOD LEVEL; BIOACCUMULATION; CELL ACTIVATION; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER FIBROSIS; LIVER FUNCTION; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; STELLATE CELL; SURVIVAL RATE; WESTERN BLOTTING; ANIMAL; BILE DUCT; C57BL MOUSE; CELL CULTURE; CELL CYCLE CHECKPOINT; CYTOLOGY; DRUG EFFECTS; LIGATION; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; SURGERY;

ACTINS; ANIMALS; BILE DUCTS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; CYCLOOXYGENASE 2; HEPATIC STELLATE CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LIGATION; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NAPHTHALENES; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84918819722     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12590     Document Type: Article

References (31)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Bataller R, Brenner DA (2005). Liver fibrosis. J Clin Invest 115: 209-218.
3. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F et al. (2002). Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1: 937-941.
4. Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R (2004). Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 321: 413-423.
5. Branton MH, Kopp JB (1999). TGF-beta and fibrosis. Microbes Infect 1: 1349-1365.
6. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR (2001). Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25: 562-568.
7. Cheng J, Imanishi H, Amuro Y, Hada T (2002). NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 99: 755-761.
8. Elsharkawy AM, Oakley F, Mann DA (2005). The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10: 927-939.
9. Friedman SL (2000). Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250.
10. Furst DE (1997). Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum 26 (6 Suppl. 1): 21-27.
11. Kaimori A, Potter JJ, Choti M, Ding Z, Mezey E, Koteish AA (2010). Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 52: 1033-1045.
12. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
13. Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC et al. (2007). Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 356: 233-238.
14. Liu Y, Wang Z, Wang J, Lam W, Kwong S, Li F et al. (2013). A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-beta and vascular endothelial growth factor signalling. Liver Int 33: 504-515.
15. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA (2007). Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 14: 275-285.
16. Marra F, Arrighi MC, Fazi M, Caligiuri A, Pinzani M, Romanelli RG et al. (1999). Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 30: 951-958.
17. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
18. Moreira RK (2007). Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 131: 1728-1734.
19. Novo E, Marra F, Zamara E, Valfre di Bonzo L, Monitillo L, Cannito S et al. (2006). Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 55: 1174-1182.
20. Park KC, Kim SW, Park JH, Song EH, Yang JW, Chung HJ et al. (2011). Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci 102: 343-350.
21. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
22. Pellicoro A, Ramachandran P, Iredale JP (2012). Reversibility of liver fibrosis. Fibrogenesis Tissue Repair 5 (Suppl. 1): S26.
23. Qin L, Han YP (2010). Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis. Am J Pathol 177: 1915-1928.
24. Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N (2000). Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 60: 2085-2089.
25. Ramm GA, Shepherd RW, Hoskins AC, Greco SA, Ney AD, Pereira TN et al. (2009). Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 49: 533-544.
26. Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, Scanga A et al. (2003). The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem 278: 8083-8090.
27. Rodriguez-Salvador J, Armas-Pineda C, Perezpena-Diazconti M, Chico-Ponce de Leon F, Sosa-Sainz G, Lezama P et al. (2005). Effect of sodium butyrate on pro-matrix metalloproteinase-9 and-2 differential secretion in pediatric tumors and cell lines. J Exp Clin Cancer Res 24: 463-473.
28. Rombouts K, Knittel T, Machesky L, Braet F, Wielant A, Hellemans K et al. (2002). Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol 37: 788-796.
29. Schuppan D, Kim YO (2013). Evolving therapies for liver fibrosis. J Clin Invest 123: 1887-1901.
30. Watanabe T, Tajima H, Hironori H, Nakagawara H, Ohnishi I, Takamura H et al. (2011). Sodium valproate blocks the transforming growth factor (TGF)-beta1 autocrine loop and attenuates the TGF-beta1-induced collagen synthesis in a human hepatic stellate cell line. Int J Mol Med 28: 919-925.
31. Yamaguchi K, Lantowski A, Dannenberg AJ, Subbaramaiah K (2005). Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem 280: 32569-32577.